HONG KONG, June 18, 2026
Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), has announced the successful completion of first-in-human dosing in the Phase I clinical study of ISM8969, a novel, orally available, brain-penetrant NLRP3 inflammasome inhibitor being developed for chronic neuroinflammation and neurodegenerative diseases, including Parkinson’s disease. The milestone represents the first clinical achievement under Insilico’s strategic co-development collaboration with Hygtia Therapeutics and marks another significant validation of the company’s AI-driven drug discovery platform. The randomized, double-blind, placebo-controlled Phase I trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISM8969 in healthy volunteers and obese adults at risk of cardiovascular disease. The advancement of ISM8969 from an AI-generated concept to clinical testing highlights the growing impact of artificial intelligence in accelerating drug discovery and transforming the future of pharmaceutical innovation.
AI-Powered Drug Discovery Advances Into Human Testing
The progression of ISM8969 into Phase I clinical development demonstrates the potential of AI-enabled drug discovery to significantly shorten traditional development timelines. Insilico utilized its proprietary Chemistry42 platform to design and optimize the small-molecule inhibitor, overcoming one of the industry’s longstanding challenges: developing an NLRP3 inhibitor capable of effectively crossing the blood-brain barrier. The NLRP3 inflammasome plays a critical role in the body’s innate immune response, but chronic overactivation contributes to excessive inflammation and neuronal damage associated with neurodegenerative disorders.
By selectively inhibiting this pathway, ISM8969 is designed to reduce pathological neuroinflammation while supporting neuronal health and function. Researchers believe that effective modulation of NLRP3 could provide a new therapeutic strategy for diseases characterized by progressive neurodegeneration, including Parkinson’s disease and other central nervous system disorders with significant unmet medical needs.
Phase I Study Designed to Evaluate CNS Penetration and Safety
Advertisement
The ongoing Phase I clinical trial is being conducted in Australia and is expected to enroll 100 participants, including healthy volunteers and obese adults at elevated cardiovascular risk. The study incorporates both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts to comprehensively assess safety and dose-related effects. In addition to standard pharmacokinetic and pharmacodynamic analyses, investigators will collect cerebrospinal fluid (CSF) samples to evaluate central nervous system penetration and characterize drug activity within the target compartment.
These data are expected to provide crucial insights into dose selection and support future clinical development decisions. Successful demonstration of CNS exposure would represent a key differentiator for ISM8969, as many currently investigated NLRP3 inhibitors remain largely restricted to peripheral tissues and may not adequately address neuroinflammatory processes occurring within the brain.
Strategic Collaboration Strengthens Neuroscience Development
The advancement of ISM8969 also marks an important milestone in Insilico’s global collaboration with Hygtia Therapeutics, an incubatee supported by Fosun Health Capital and Fosun Pharma. Under the agreement, both companies share global rights to the program, with Insilico leading investigational new drug activities and Phase I development. Insilico remains eligible to receive up to $66 million in upfront and milestone payments as the program progresses. Preclinical studies demonstrated that ISM8969 possesses a favorable druggability profile, strong anti-inflammatory activity, promising pharmacological characteristics, and efficacy across multiple disease models.
Since 2021, Insilico has nominated 31 preclinical candidates, with 13 programs receiving IND approval or clearance, underscoring the productivity of its AI-native research platform. As artificial intelligence continues to reshape the biotechnology landscape, the successful initiation of human testing for ISM8969 represents another milestone in demonstrating how advanced computational technologies can accelerate the development of innovative therapies for complex diseases and potentially improve outcomes for patients worldwide.
Source: Insilico Medicine press release
